Inspiration Healthcare Group plc
("Inspiration Healthcare", the "Company" or the "Group")
Exercise of options and Total Voting Rights
Inspiration Healthcare Group plc (AIM: IHC), the global medical technology company announces that, pursuant to the exercise of options at nil cost under the Inspiration Healthcare Group plc Long Term Incentive Plan (the "LTIP") by current and former employees of the Group, a total of 147,838 new ordinary shares of 10p each in the Company ("New Ordinary Shares") have been issued and allotted by the Company. Application has been made for the New Ordinary Shares to be admitted to AIM ("Admission") and such Admission is expected to become effective at 8.00am on or around 25 January 2021. The New Ordinary Shares shall rank pari passu with the existing Ordinary Shares in issue.
Additionally, the Company has recently established the Inspiration Healthcare Group plc Employee Benefit Trust (the "EBT"). It is intended that the EBT is used in the future to help satisfy awards made under the LTIP.
Total Voting Rights
For the purpose of the Disclosure Guidance and Transparency Rules of the FCA, following the above issue of New Ordinary Shares, the issued share capital of the Company will comprise 68,121,447 Ordinary Shares. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the FCA's Disclosure Guidance and Transparency Rules.
Enquiries:
Inspiration Healthcare Group plc Neil Campbell, Chief Executive Officer Jon Ballard, Chief Financial Officer |
Tel: 01455 840555
|
Nominated Adviser & Broker Cenkos Securities plc Mark Connelly Stephen Keys |
Tel: 0207 397 8900
|
Cadogan PR Alex Walters |
Tel: 07771 713608 |
About Inspiration Healthcare http://www.inspiration-healthcare.com
Inspiration Healthcare (AIM: IHC) is a global provider of medical technology for use in critical care & operating theatres. The Company provides high-quality, innovative products to patients around the world which help to improve patient outcomes, and it actively invests in innovative product opportunities and disruptive technologies.
Through investment in research and development the Company has six key own-brand products that can be used within the first 6 hours of life to help premature and sick babies; helping with assessment, resuscitation, stabilisation as well as preventing brain damage. Additionally, the Company has a range of products for maintaining normothermia pre- during and post-surgery.
In September 2019, the Company acquired Vio Holdings a designer, manufacturer and supplier of single-use respiratory products and sterile medical consumables for £4 million and in June 2020 the Company acquired SLE, a leading global provider of neonatal ventilation products for £18 million. Over 90% of SLE's revenues are generated from sales outside of the UK with a significant proportion of these in the Asia Pacific and the Middle East. When combined, the Group generates approximately 60 per cent. of its revenue from exports.
With product availability extending to over 50 countries through a distribution network, Inspiration Healthcare's success has been built on continuous innovation, excellent customer service and an inherent commitment to improving patient outcomes, working in close collaboration with key opinion leaders across the globe.
In the U.K. and Ireland, the Company has a direct sales team selling Inspiration Healthcare Branded and complementary products from third parties, with an additional range of home healthcare products. This is supported by Technical Support for planned preventative maintenance and emergency assistance.
Further information on Inspiration Healthcare can be seen at www.inspiration-healthcare.com